Moderna (NASDAQ:MRNA) Stock Falls 3.6% – What’s Next?

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) dropped 3.6% on Monday. The company traded as low as $212.50 and last traded at $215.27. Approximately 6,997,765 shares were traded during trading, a decline of 44% from the average session volume of 12,547,155 shares. The stock had previously closed at $223.37.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on MRNA. Evercore raised their target price on Moderna from $50.00 to $80.00 in a research note on Thursday, October 8th. Wolfe Research upgraded shares of Moderna from an “underperform” rating to a “peer perform” rating in a research report on Tuesday, August 25th. Rothschild & Co Redburn cut shares of Moderna from a “neutral” rating to a “sell” rating and upped their price target for the stock from $40.00 to $81.00 in a research report on Thursday, September 3rd. Morgan Stanley raised their price target on shares of Moderna from $89.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Moderna in a research report on Wednesday, September 9th. Six research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $113.75.

Read Our Latest Stock Analysis on MRNA

Moderna Stock Down 3.6%

The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62. The firm has a market capitalization of $87.10 billion, a price-to-earnings ratio of -30.32 and a beta of 1.16. The firm has a fifty day moving average price of $201.67 and a 200 day moving average price of $96.41.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its quarterly earnings data on Friday, November 6th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The firm had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $890.25 million. During the same quarter last year, the business earned ($0.51) earnings per share. The business’s revenue for the quarter was up 29.2% compared to the same quarter last year. As a group, sell-side analysts expect that Moderna, Inc. will post -5.14 EPS for the current fiscal year.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 34,836 shares of Moderna stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the sale, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. The trade was a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 40,294 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the completion of the transaction, the president owned 1,525,858 shares of the company’s stock, valued at $219,921,913.54. This trade represents a 2.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 197,251 shares of company stock worth $33,875,904. 10.80% of the stock is owned by insiders.

Institutional Trading of Moderna

Hedge funds and other institutional investors have recently modified their holdings of the company. State of Tennessee Department of Treasury grew its stake in shares of Moderna by 21.7% in the 3rd quarter. State of Tennessee Department of Treasury now owns 82,511 shares of the company’s stock valued at $15,889,000 after buying an additional 14,689 shares in the last quarter. Bank OZK bought a new stake in Moderna during the 3rd quarter worth about $1,775,000. Empirical Finance LLC lifted its holdings in Moderna by 3.6% in the third quarter. Empirical Finance LLC now owns 9,767 shares of the company’s stock valued at $1,881,000 after buying an additional 341 shares during the period. Entropy Technologies LP acquired a new stake in shares of Moderna during the third quarter worth $480,000. Finally, Jump Financial LLC raised its position in Moderna by 470.7% during the third quarter. Jump Financial LLC now owns 154,274 shares of the company’s stock worth $29,709,000 after acquiring an additional 127,243 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

About Moderna

(Get Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Recommended Stories

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.